Skip to main content
logo
Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
31.80
+0.90 (2.91%)
At close: Mar 23, 2026, 4:00 PM EDT
31.85
+0.05 (0.16%)
Pre-market: Mar 24, 2026, 6:17 AM EDT

Celldex Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.557.026.882.364.65
Revenue Growth (YoY)
-77.99%1.98%192.07%-49.32%-37.30%
Gross Profit
1.557.026.882.364.65
Selling, General & Admin
43.8438.5530.9127.220.49
Research & Development
245.07163.55118.0182.2653.31
Other Operating Expenses
---8.142.1
Total Operating Expenses
288.91202.1148.93117.5975.89
Operating Income
-287.37-195.08-154.54-115.23-71.24
Interest Income
28.6137.2213.112.910.51
Total Non-Operating Income (Expense)
28.6137.2213.112.910.51
Pretax Income
-258.76-157.86-141.43-112.33-70.74
Provision for Income Taxes
-----0.23
Net Income
-258.76-157.86-141.43-112.33-70.51
Net Income to Common
-258.76-157.86-141.43-112.33-70.51
Shares Outstanding (Basic)
6664484743
Shares Outstanding (Diluted)
6664484743
Shares Change (YoY)
3.15%32.91%3.33%9.37%44.64%
EPS (Basic)
-3.90-2.45-2.92-2.40-1.64
EPS (Diluted)
-3.90-2.45-2.92-2.40-1.64
Free Cash Flow
-213.66-159.7-109.11-105.56-62.16
Free Cash Flow Per Share
-3.22-2.48-2.25-2.25-1.45
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-18599.81%-2778.89%-2244.94%-4889.01%-1531.78%
Profit Margin
-16748.03%-2248.76%-2054.46%-4765.59%-1516.04%
FCF Margin
-13829.06%-2274.89%-1584.97%-4478.57%-1336.44%
EBITDA
-283.99-191.9-151.53-112.34-68.18
EBITDA Margin
-18381.04%-2733.63%-2201.25%-4766.14%-1465.81%
EBIT
-287.37-195.08-154.54-115.23-71.24
EBIT Margin
-18599.81%-2778.89%-2244.94%-4889.01%-1531.78%
Effective Tax Rate
0.00%0.00%0.00%0.00%0.32%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q